RADNOSTIX INC INIS
RADNOSTIX INC (INIS) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $13.1M at a -6.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.91 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INIS | RADNOSTIX INC | 3/9 | — | — | -6% |
| ELSE | ELECTRO SENSORS INC | 5/9 | — | 88.3 | — |
| CLIR | ClearSign Technologies Corp | 2/9 | — | — | — |
| FCUV | FOCUS UNIVERSAL INC. | 2/9 | -1.6 | — | — |
| SENS | Senseonics Holdings, Inc. | 6/9 | — | — | +56.9% |
| SYPR | SYPRIS SOLUTIONS INC | 2/9 | -2.92 | — | -14.5% |
| HURC | HURCO COMPANIES INC | 4/9 | 9.02 | — | -4.3% |
About RADNOSTIX INC
Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The Theranostics Products segment produces and distributes Iodine-131 generic drug product and various isotopically pure radiochemicals for medical, industrial, and research applications. The Cobalt Products segment produces cobalt-60 products and services, the fabrication of cobalt-60 sealed sources for radiation therapy, industrial and medical applications, and recycling of expended cobalt-60 sources. The Calibration & Reference Products segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry. This segment also offers flood sources, dose calibrators, cylinder phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and various specialty design items. The Medical Devices segment develops EasyFill Automated Capsule System, a robotic lab device. The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The company sells its products directly to end users and distributors. The company was formerly known as International Isotopes Inc. and changed its name to Radnostix, Inc. in December 2025. Radnostix, Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
FAQ
Is INIS financially healthy?
RADNOSTIX INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does INIS pay a dividend?
No, RADNOSTIX INC does not currently pay a dividend.
How profitable is INIS?
In FY2025, RADNOSTIX INC had a net margin of -6.9% and a return on equity of -24.6%.
Is INIS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on RADNOSTIX INC: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.